Use of class I histone deacetylase inhibitor romidepsin in combination regimens
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of class I histone deacetylase inhibitor romidepsin in combination regimens
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 8, Pages 1755-1765
Publisher
Informa UK Limited
Online
2016-04-27
DOI
10.3109/10428194.2016.1160082
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma
- (2015) A. McBride et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma
- (2015) Enrica Marchi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma
- (2015) S. Jain et al. CLINICAL CANCER RESEARCH
- Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
- (2015) E. A. Chong et al. CLINICAL CANCER RESEARCH
- Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
- (2015) Philip T. Sager et al. Cancer Medicine
- Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
- (2015) Jehan Dupuis et al. Lancet Haematology
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
- (2014) Bertrand Coiffier et al. Journal of Hematology & Oncology
- Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
- (2014) Sarah I. Jawed et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
- (2014) Nathan H Fowler et al. LANCET ONCOLOGY
- Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
- (2013) Vivien Mak et al. JOURNAL OF CLINICAL ONCOLOGY
- Methods for Identifying Higher-Order Chromatin Structure
- (2012) Samin A. Sajan et al. Annual Review of Genomics and Human Genetics
- Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions
- (2012) O.E. Akilov et al. BRITISH JOURNAL OF DERMATOLOGY
- Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2012) Suzanne F. Jones et al. CANCER INVESTIGATION
- Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer
- (2012) Andrew J. Wilson et al. GYNECOLOGIC ONCOLOGY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin
- (2012) Youn H. Kim et al. LEUKEMIA & LYMPHOMA
- HDAC inhibitor-based therapies: Can we interpret the code?
- (2012) Maria New et al. Molecular Oncology
- A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
- (2011) S. J. Harrison et al. BLOOD
- HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
- (2011) M. Kalac et al. BLOOD
- Peripheral T-cell lymphoma
- (2011) F. M. Foss et al. BLOOD
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
- (2010) J. Kikuchi et al. BLOOD
- A work in progress: The clinical development of histone deacetylase inhibitor
- (2010) Silvia Marsoni et al. Epigenetics
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
- (2010) Nita Sally Agar et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
- (2010) R Shimizu et al. LEUKEMIA
- How I treat mycosis fungoides and Sezary syndrome
- (2009) H. M. Prince et al. BLOOD
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- (2009) Thomas E. Witzig et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines
- (2009) Wei Zhang et al. Journal of Thoracic Oncology
- Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib
- (2008) F.-T. Liu et al. BLOOD
- Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells
- (2008) Y. Dai et al. CLINICAL CANCER RESEARCH
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
- Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression
- (2007) Vinodhkumar Radhakrishnan et al. BIOMEDICINE & PHARMACOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now